Christine Hamilton and Jeffrey Spragens resign from SAB Biotherapeutics board; size cut to nine

SAB Biotherapeutics, Inc.

Christine Hamilton and Jeffrey Spragens resigned as board members effective September 30, 2025.
Board size reduced from 11 to 9 directors, per July 2025 letter agreement with RA Capital Healthcare Fund.
Resignations were not the result of any disagreement with management or company policies.
The changes follow terms of the company's July 2025 private placement of securities.

item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.